Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Quince Therapeutics, Inc. from 31 Dec 2019 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Quince Therapeutics, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Dec 2019 to 31 Mar 2025.
  • Quince Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 31 Mar 2025 was $14,983,000, a 35% decline year-over-year.
  • Quince Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $56,741,000, a 80% decline from 2023.
  • Quince Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $31,582,000, a 39% increase from 2022.
  • Quince Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $51,944,000, a 42% increase from 2021.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

Quince Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $14,983,000 -$3,865,000 -35% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q1 2024 $11,118,000 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1

Quince Therapeutics, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $56,741,000 -$25,159,000 -80% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $31,582,000 +$20,362,000 +39% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $51,944,000 +$38,001,000 +42% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $89,945,000 -$13,096,000 -17% 01 Jan 2021 31 Dec 2021 10-K 15 Mar 2023 2022 FY
2020 $76,849,000 -$39,869,000 -108% 01 Jan 2020 31 Dec 2020 10-K 01 Mar 2022 2021 FY
2019 $36,980,000 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.